Filtered By:
Specialty: Cytology
Drug: Temodar
This page shows you your search results in order of date.
Order by Relevance | Date
Total 146 results found since Jan 2013.
Cordycepin improves sensitivity to temozolomide in glioblastoma cells by down-regulating MYC
CONCLUSION: Cordycepin combined with temozolomide may down-regulate MYC through "MicroRNA in cancer, Proteoglycans in cancer, Pathways in cancer and PI3K-AKT signaling pathway", which in turn regulate the expression of MCL1, CTNNB1, MMP9, PDCD4, thus regulating cell proliferation, migration and apoptosis in glioblastoma.PMID:37695389 | DOI:10.1007/s00432-023-05347-0
Source: Cell Research - September 11, 2023 Category: Cytology Authors: Shi-Xing Zheng Jing Chen Bing-Bo Zhuang Qiang Zhang Song-Sheng Shi Guo-Liang Zhang Source Type: research
Invadopodia associated Thrombospondin-1 contributes to a post-therapy pro-invasive response in glioblastoma cells
In this study we utilized a Nanostring® Cancer Progression gene expression panel to identify candidate genes that may be involved in enhanced GBM cell invasion after treatment with clinically relevant doses of RT/TMZ. Our findings identified thrombospondin-1 (THBS1) as a pro-invasive gene that is upregulated in these cells. Immunofluorescence staining revealed that THBS1 localised within functional matrix-degrading invadopodia that formed on the surface of GBM cells. Furthermore, overexpression of THBS1 resulted in enhanced GBM cell migration and secretion of MMP-2, which was reduced with silencing of THBS1. The prelimina...
Source: Experimental Cell Research - August 17, 2023 Category: Cytology Authors: Clarissa A Whitehead Andrew P Morokoff Andrew H Kaye Katharine J Drummond Theo Mantamadiotis Stanley S Stylli Source Type: research
Targeting MAGI2-AS3-modulated Akt-dependent ATP-binding cassette transporters as a possible strategy to reverse temozolomide resistance in temozolomide-resistant glioblastoma cells
In conclusion, MAGI2-AS3 reverses TMZ resistance in glioma cells by inactivating the Akt pathway.PMID:37551766 | DOI:10.1002/ddr.22101
Source: Cell Research - August 8, 2023 Category: Cytology Authors: Zhongjun Chen Jingmin Zhou Yu Liu Hongzao Ni Botao Zhou Source Type: research
Inhibition of autophagy and induction of glioblastoma cell death by NEO214, a perillyl alcohol-rolipram conjugate
Autophagy. 2023 Aug 6:1-20. doi: 10.1080/15548627.2023.2242696. Online ahead of print.ABSTRACTGlioblastoma (GBM) is the most aggressive primary brain tumor, exhibiting a high rate of recurrence and poor prognosis. Surgery and chemoradiation with temozolomide (TMZ) represent the standard of care, but, in most cases, the tumor develops resistance to further treatment and the patients succumb to disease. Therefore, there is a great need for the development of well-tolerated, effective drugs that specifically target chemoresistant gliomas. NEO214 was generated by covalently conjugating rolipram, a PDE4 (phosphodiesterase 4) in...
Source: Autophagy - August 7, 2023 Category: Cytology Authors: Mengting Ou Hee-Yeon Cho Jie Fu Thu Zan Thein Weijun Wang Stephen D Swenson Radu O Minea Apostolos Stathopoulos Axel H Sch önthal Florence M Hofman Liling Tang Thomas C Chen Source Type: research
Preclinical efficacy of LP-184, a tumor site activated synthetic lethal therapeutic, in glioblastoma
CONCLUSIONS: These results establish LP-184 as a promising chemotherapeutic for GBM with enhanced efficacy in intrinsic or spironolactone-induced TC-NER deficient tumors.PMID:37494541 | DOI:10.1158/1078-0432.CCR-23-0673
Source: Cell Research - July 26, 2023 Category: Cytology Authors: Bachchu Lal Aditya Kulkarni Joseph McDermott Rana Rais Jesse Alt Ying Wu Hernando Lopez-Bertoni Sophie Sall Umesh Kathad Jianli Zhou Barbara S Slusher Kishor Bhatia John Laterra Source Type: research
First Report of Management of Sequential Small Cell Transformation and ALK I1171T Mutation as Resistance Mechanisms in a Patient With ALK-EML4 Fused Non-Small Cell Lung Adenocarcinoma With a Novel Combination of Temozolomide and Lorlatinib: A Case Report
JTO Clin Res Rep. 2023 Jun 15;4(7):100536. doi: 10.1016/j.jtocrr.2023.100536. eCollection 2023 Jul.ABSTRACTALK-EML4 fusion-positive lung adenocarcinomas (LUADs) are effectively treated with ALK tyrosine kinase inhibitors, but most patients eventually develop resistance to these drugs owing to ALK-dependent or independent mechanisms. Endothelial to mesenchymal transformation with SCLC development is an ALK-independent mechanism of resistance that has not been previously reported with sequential ALK I1171T mutation while the patient is on treatment for the SCLC. Here, we report the first case of sequential SCLC transformatio...
Source: Cell Research - July 17, 2023 Category: Cytology Authors: Umair Majeed Shenduo Li Karan Seegobin Aziza Nassar Rami Manochakian Yujie Zhao Yanyan Lou Source Type: research
CCL21-CCR7 signaling promotes microglia/macrophage recruitment and chemotherapy resistance in glioblastoma
Cell Mol Life Sci. 2023 Jun 14;80(7):179. doi: 10.1007/s00018-023-04788-7.ABSTRACTGlioblastoma (GBM) is the most common and fatal primary tumor of the central nervous system (CNS) and current treatments have limited success. Chemokine signaling regulates both malignant cells and stromal cells of the tumor microenvironment (TME), constituting a potential therapeutic target against brain cancers. Here, we investigated the C-C chemokine receptor type 7 (CCR7) and the chemokine (C-C-motif) ligand 21 (CCL21) for their expression and function in human GBM and then assessed their therapeutic potential in preclinical mouse GBM mod...
Source: Cellular and Molecular Life Sciences : CMLS - June 14, 2023 Category: Cytology Authors: Luiz Henrique Geraldo Celina Garcia Yunling Xu Felipe Saceanu Leser Izabella Grimaldi Eduardo Sabino de Camargo Magalh ães Joost Dejaegher Lien Solie Cl áudia Maria Pereira Ana Helena Correia Steven De Vleeschouwer Bertrand Tavitian Nathalie Henriques S Source Type: research
